FMP
NASDAQ
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
1.04 USD
-0.03 (-2.88%)
Valuation Date:
Apr 24, 2024 4:00 PM
Share Price on Valuation Date
$1.04
Stock Beta
2.648
Shares Outstanding
34756400